Ascendis Pharma price target raised to $254 by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald raised its price target on Ascendis Pharma (NASDAQ:ASND) to $254.00 from its previous target, while maintaining an Overweight rating on the stock. The company’s shares have shown remarkable strength, delivering a 52% gain year-to-date and currently trading near its 52-week high of $216.45.

The firm updated its patient flow model for Yorvipath, projecting third-quarter sales of $179 million, which aligns closely with the FactSet consensus estimate of $177 million. According to InvestingPro data, the company has demonstrated strong revenue growth of 54.5% over the last twelve months, with analysts maintaining a highly bullish consensus rating of 1.21 (where 1 is Strong Buy).

Cantor Fitzgerald noted that Wall Street analysts have now caught up to the initial strong launch trajectory of Yorvipath, with most investors expecting "steady" growth of approximately 1,500 new patient additions quarter-over-quarter.

The research firm indicated that any differences versus consensus estimates are likely to be marginal, potentially due to exchange rate fluctuations, acceleration of converts, or seasonality factors.

Cantor Fitzgerald reiterated its Overweight rating on Ascendis Pharma stock ahead of the company’s upcoming third-quarter financial results.

In other recent news, Ascendis Pharma reported its Q2 2025 earnings, significantly surpassing analysts’ expectations. The company achieved an earnings per share of -0.82, compared to the anticipated -1.27, resulting in a 35.43% surprise. Revenue also exceeded forecasts, coming in at €158 million against the expected €142.38 million, marking an 11.01% surprise. Additionally, Ascendis Pharma has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP, a treatment for children with achondroplasia, based on extensive clinical trial data.

In the realm of analyst recommendations, UBS has reiterated its Buy rating and set a price target of $307.00 for Ascendis Pharma, following competitor MBX’s clinical trial results. Furthermore, BofA Securities continues to rate Ascendis Pharma as a Buy with a $230.00 price target, highlighting it as a top pick for 2025 due to the strong global launch of Yorvipath for hypoparathyroidism. These recent developments underscore the company’s strategic advancements and its continued focus on expanding treatment options in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.